CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, Di Domenicantonio A, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Alì G, Di Desidero T, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P.
Antonelli A, et al. Among authors: berti p.
J Clin Endocrinol Metab. 2012 Apr;97(4):E528-36. doi: 10.1210/jc.2011-1987. Epub 2012 Jan 25.
J Clin Endocrinol Metab. 2012.
PMID: 22278419